Britain and America have signed a important commercial pact that will guarantee zero tariffs on UK pharmaceutical exports entering the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on drugs through the public health system. This pledge ensures that duties on these vital products will stay at zero for a period of 36 months.
This agreement comes after previous threats to dramatically increase duties on patented pharmaceutical imports, with increases mentioned reaching 100%.
"This agreement with the UK strengthens the worldwide climate for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. medicine commerce," an announcement declared.
Trade Impact
Drugs constitute one of the the United Kingdom's largest export categories to the America, which is by far the primary market for large companies like GSK and AstraZeneca.
Statistics show that in the year leading up to September, the UK sold medicines valued at over eleven billion pounds to the US. This amount accounted for 17.4% of total UK exports in that period.
"This guarantee protects employment, increases funding and paves the way for the UK to become a global hub for life sciences," a minister remarked.
Specific UK Commitments
The deal includes several specific commitments from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to double total NHS spending on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. In the past, refunds exceeded 20%.
Recent Tensions
The pact follows a ongoing dispute between the drug companies and the ministers over drug pricing and NHS adoption.
The disagreement were heightened by arguments that American consumers were charged significantly more for the same drugs than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been delayed or abandoned, while major investments have been directed toward American operations.
The Science Minister stated that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
